Financial Performance and Projections - The company is an early-stage entity with a history of financial losses and expects to incur significant expenses and continuing losses until its powerhouses become commercially viable [76]. - The company’s ability to forecast future results is limited due to its limited commercial operating history and evolving industry dynamics [80]. - The company anticipates that its operating expenses will increase over the next several years, necessitating additional capital from external sources [83]. - The company does not expect to generate meaningful revenue until the development and commercialization of the Aurora product line are finalized [243]. - The company’s financial results may vary significantly from quarter to quarter due to factors such as customer contract terms and demand variability [251][252]. - Future cash flows may grow less quickly than anticipated or decline if the company cannot meet market demands or if market opportunity estimates prove incorrect [182]. - The company’s reliance on government policies and incentives for financing may pose risks if these policies change or are eliminated [245][246]. - The company may need to delay or discontinue research and development programs if adequate funding is not secured, impacting its strategic objectives [237][240]. Regulatory and Compliance Risks - The company is subject to various laws and regulations, including those related to nuclear technologies, which may change and impact operations and financial condition [183]. - Compliance with new regulations may increase general and administrative expenses and divert management attention, potentially affecting sales and profitability [184]. - The NRC has not licensed any powerhouse in the Aurora product family, and no advanced fission technology has been approved for commercial operation in the U.S. [198]. - The company has not received any approval or licensing for its planned facilities, and the timing of such approvals is uncertain [195]. - The Department of Energy (DOE) and Nuclear Regulatory Commission (NRC) have the authority to change regulatory requirements, which could lead to additional expenses for compliance [209]. - The company is subject to complex compliance requirements regarding data privacy and security, which could result in legal claims and significant costs if not adhered to [165]. - The company is subject to Section 404 of the Sarbanes-Oxley Act, requiring effective internal controls over financial reporting, which are more stringent than those for private companies [264]. - Failure to implement required internal controls could lead to regulatory scrutiny and a loss of public and investor confidence, adversely affecting the company's financial condition [265]. Operational and Supply Chain Challenges - The company relies on a limited number of suppliers for specialized materials and components, which may lead to operational difficulties if these suppliers fail to deliver [76]. - The company’s construction and delivery timelines for powerhouses may be extended due to various factors, including supply chain constraints and contractor performance [84]. - The company may face challenges in securing adequate HALEU supplies on a predictable schedule and at acceptable costs due to regulatory and infrastructure issues [94]. - The ongoing military conflict in Ukraine has resulted in supply chain risks for sourcing HALEU, increasing costs for uranium enrichment services [170]. - Inflation has led to higher interest rates, shipping costs, and material costs, which could adversely affect the company's competitiveness and operational capabilities [167]. - The company relies on global supply chains for components, and changes in trade policies could increase costs and disrupt operations [224]. Market and Competitive Landscape - The company may face increased competition from existing and new technologies, which could pressure pricing and market share [129]. - The cost of electricity and heat generated from the company's powerhouses may not be competitive with other energy sources, impacting business performance [135]. - Market acceptance of independent developer fission power plants may be hindered, potentially slowing market penetration and revenue growth [116]. - The market for recycling nuclear fuel in the U.S. has not yet been established, and any material changes to market conditions could adversely affect the company's business and financial results [138]. - The market for technologies using artificial intelligence is expected to grow, but if it does not, it may reduce customer demand for power and heat, impacting the company's offerings [180]. Strategic and Development Risks - The company plans significant operational expansion, including hiring new personnel and completing the designs and construction of powerhouses and fuel fabrication facilities [119]. - Continued growth may strain resources, leading to operational difficulties such as hiring challenges and delays in production, which could adversely affect financial condition [121]. - The company faces risks such as higher-than-expected research and development costs, delays in obtaining regulatory approvals, and competition from established market entrants, which could materially impact its financial condition [141]. - The company is exploring the use of artificial intelligence technologies to improve operational efficiency, but the reliability of these technologies is unproven and may lead to unexpected impacts [147]. Legal and Liability Concerns - The company may incur costs related to government inquiries, regulatory investigations, or litigation, impacting its financial performance [257]. - The company may face risks related to securities litigation, which could result in significant legal expenses and negatively impact its business [256]. - The company anticipates facing claims regarding the infringement of third-party intellectual property rights, which may lead to insufficient indemnification or damages under license agreements [157]. - The company seeks to cover gaps in nuclear liability coverage, but such coverage may not always be possible, potentially affecting financial condition [219]. Environmental and Political Factors - Public perception and political support for nuclear power are critical for the company's success, as negative public sentiment could delay or prevent the licensing and construction of new facilities [145]. - Changes in federal, state, and local government policies and priorities could adversely affect regulatory oversight, supply chain availability, and financial incentives [206]. - The company currently operates with bipartisan support for advanced nuclear power technologies, but changes in the political climate could impact operations and business plans [207]. - Climate change poses risks to the company's operations and supply chain, potentially leading to increased costs and operational disruptions [177].

Financial Performance - IZEA reported a record profitability swing of $18.9 million, achieving break-even on $31.2 million of revenue for FY 2025[1]. - Net income for FY 2025 was $42,326, compared to a net loss of $18.9 million in the previous year, which included $6.9 million in one-time charges[6]. - Total revenue for Q4 2025 was $6.1 million, a decline of $3.8 million or 39% compared to Q4 2024, primarily due to strategic repositioning and the exit of lower-margin customer relationships[4]. - Total revenue for Q4 2025 was $6,063,878, a decrease of 45% compared to $11,002,517 in Q4 2024[23]. - For the full year 2025, total revenue was $31,237,853, a decrease of 13% from $35,881,010 in 2024[27]. - Managed Services Revenue for Q4 2025 was $6,027,710, down 45% from $10,885,094 in Q4 2024, with On-Going Operations contributing 99% of this revenue[27]. - SaaS Services Revenue for the full year 2025 was $213,272, down 74% from $822,987 in 2024[27]. - The company reported a total comprehensive loss of $(1,171,102) for Q4 2025, compared to $(4,396,551) in Q4 2024[25]. Cost Management - Total costs and expenses decreased by 46% to $7.7 million compared to $14.2 million in the prior year[6]. - Total costs and expenses for Q4 2025 were $7,674,257, down from $14,181,270 in Q4 2024[23]. Adjusted Metrics - Adjusted EBITDA for Q4 2025 was $(0.9) million, an improvement of $1.1 million year-over-year from a loss of $2.0 million[9]. - Adjusted EBITDA for Q4 2025 was $(936,178), compared to $(2,021,485) in Q4 2024, indicating a narrowing of losses[29]. Shareholder Actions - The company has committed to repurchasing up to $10.0 million of its stock, having purchased 561,950 shares for $1.4 million under the program[10]. - Basic loss per share for Q4 2025 was $(0.07), compared to $(0.27) in Q4 2024[23]. - The weighted average common shares outstanding for Q4 2025 was 17,074,681, slightly up from 16,965,350 in Q4 2024[23]. Strategic Initiatives - Managed Services bookings declined 18.7% to $9.0 million from $11.0 million in the prior year, reflecting a shift toward larger, recurring enterprise accounts[6]. - The company secured new business partnerships with major brands including Netflix Games and Danone, enhancing its market position[6]. - IZEA's strategic focus on larger enterprise accounts is expected to drive future growth and profitability[3].

Financial Performance - Generated revenue of $24.6 million in Q3 FY26, an increase of 63% compared to the prior year period[4] - Expanded gross margin to 52.6% in Q3 FY26, up from 43.4% in the prior year period[4] - Increased FY26 revenue guidance to $93 million, representing growth of 55% compared to FY25[7] - 5,462 prescriptions were written for the ASSURE® system, an increase of 58% compared to the prior year period[5] Losses and Expenses - GAAP net loss was $34.2 million in Q3 FY26, compared to a net loss of $21.8 million in the prior year period[5] - Adjusted EBITDA loss was $21.2 million in Q3 FY26, compared to an adjusted EBITDA loss of $16.3 million in the prior year period[5] - GAAP operating expenses were $47.7 million in Q3 FY26, up from $27.1 million in the prior year period[5] - The increase in operating expenses was attributed to accelerated commercial expansion and public company costs[5] - Net loss for the nine months ended January 31, 2026, was $92,777,000, compared to a net loss of $62,703,000 for the same period in 2025, indicating a 47.9% increase in losses[22] - Net cash used in operating activities for the nine months ended January 31, 2026, was $62,983,000, compared to $53,552,000 for the same period in 2025, a 17.9% increase[22] Cash and Assets - Cash and cash equivalents totaled $291 million as of January 31, 2026, including proceeds from a public offering[12] - Cash and cash equivalents rose to $291,321,000 as of January 31, 2026, compared to $237,595,000 on April 30, 2025, reflecting a 22.5% increase[20] - Total assets increased to $379,342,000 as of January 31, 2026, up from $295,744,000 on April 30, 2025, representing a growth of 28.3%[20] - The end of period cash, cash equivalents, and restricted cash reached $291,655,000 as of January 31, 2026, compared to $54,686,000 at the end of the previous year[22] Liabilities and Equity - Total current liabilities increased to $42,931,000 as of January 31, 2026, from $37,977,000 on April 30, 2025, marking a rise of 13.7%[20] - Shareholders' equity grew to $287,989,000 as of January 31, 2026, up from $205,406,000 on April 30, 2025, an increase of 40.0%[20] - The company reported a significant increase in additional paid-in capital, rising to $842,666,000 as of January 31, 2026, from $674,306,000 on April 30, 2025, a growth of 25.0%[20] Strategic Initiatives - The company entered into a strategic collaboration with Biobeat Technologies to enhance its market position[2] Cash Flows - Proceeds from the issuance of common stock amounted to $149,291,000 during the nine months ended January 31, 2026[22] - Cash flows from investing activities totaled a net cash outflow of $30,571,000 for the nine months ended January 31, 2026, compared to $15,904,000 in the prior year[22]

Financial Performance - Total revenue for the fourth quarter of 2025 was $13.8 million, compared to $9.4 million for the same period in 2024, representing a 47.5% increase[16] - Net loss for Q4 2025 was $47.2 million, or $0.21 per share, compared to a net loss of $33.0 million, or $0.15 per share, for Q4 2024[12] - Total operating expenses for the full year 2025 were $219.2 million, compared to $174.6 million for 2024, reflecting a 25.5% increase[16] - The accumulated deficit as of December 31, 2025, was $1.44 billion, compared to $1.27 billion at the end of 2024[17] Research and Development - Research and Development (R&D) expenses for Q4 2025 were $48.9 million, up from $36.1 million in Q4 2024, marking a 35.5% increase[11] - In the PROSERA study, seralutinib showed a placebo-adjusted improvement in six-minute walk distance of approximately +13.3 meters at Week 24, although it did not meet the prespecified statistical threshold[6] Regulatory and Clinical Updates - The company plans to request a Type C meeting with the FDA in June 2026 to discuss the PROSERA dataset and potential regulatory paths forward[10] - Enrollment in the Phase 3 SERANATA Study in PH-ILD has been paused while the company evaluates the implications of PROSERA results[5] Operational Changes - The company implemented a reduction in force to align resources with near-term priorities[8] - Cash, cash equivalents, and marketable securities totaled $136.9 million as of December 31, 2025, down from $294.5 million at the end of 2024[17]

HSA Market and Growth - As of January 31, 2026, the company administered 10.6 million HSAs with total balances of $36.5 billion, and 7.2 million complementary CDBs, resulting in a total of 17.8 million accounts[16]. - The company increased its market share in the HSA market from 4% in December 2010 to 20% as of June 2025, becoming the largest HSA provider by number of accounts and the second largest by HSA assets[18]. - In fiscal 2025, the company acquired the BenefitWallet HSA portfolio, which included approximately 616,000 HSAs and $2.7 billion in HSA assets, for a purchase price of $425 million[21]. Revenue Generation - Revenue is primarily generated from service, custodial, and interchange sources, with service revenue including fees from clients and account holders for administration services[20]. - The percentage of HSA cash held in the company's Enhanced Rates offering has increased, positively impacting custodial revenue due to higher yields compared to Basic Rates[48]. - HealthEquity's revenue is significantly derived from tax-advantaged healthcare account holders, with no single customer accounting for more than 10% of total revenue[304]. Technology and Innovation - The company offers a differentiated consumer experience through its technology and service-driven culture, which is designed to optimize the management of healthcare costs[39]. - The company continues to invest in technology solutions, including AI tools, to enhance customer service and operational efficiencies[51]. - The proprietary cloud-based technology solution allows for rapid implementation of product enhancements across the user base, reducing the need for clients to maintain hardware and software[52]. - The technology platforms enable members to manage healthcare savings, spending, and investments, including features for bill payment and access to healthcare consumer specialists[53]. - The proprietary technology solution is designed to integrate data from various sources, deepening partnerships with Network Partners and other ecosystem partners[51]. Operational Performance and Strategy - The business model provides strong visibility into future operating performance, with most accounts opened before the start of the fiscal year[19]. - The company has a scalable operating model primarily accessed through cloud-based technology platforms, leading to declining service costs over time as HSA member balances grow[47]. - The company has a selective acquisition strategy, focusing on HSA portfolios that strengthen service offerings, with ongoing evaluations of potential opportunities[50]. - Strong retention rates for HSA members are attributed to high switching costs and integration with the broader healthcare system[49]. Financial Position - As of January 31, 2026, HealthEquity held HSA Assets of $36.5 billion, an increase from $32.1 billion in 2025[307]. - The company reported cash and cash equivalents of $318.9 million as of January 31, 2026, compared to $295.9 million in 2025[313]. - Client-held funds amounted to $1,090 million as of January 31, 2026, up from $896 million in 2025[312]. - The company had $361.9 million in outstanding long-term debt under its Revolving Credit Facility as of January 31, 2026, with a variable interest rate of 5.02%[314]. Team Member Engagement and Turnover - Total team member turnover for the fiscal year ended January 31, 2026, was 25%, with voluntary turnover at 10%[80]. - The team member engagement score was 78% favorable as of October 2025, based on an 86% participation rate[80]. Regulatory and Market Risks - The company is subject to extensive regulations, including IRS regulations governing HSAs, which impact its operational framework[58]. - The company is subject to market risks, including inflation and interest rate fluctuations, which could adversely affect its operating results[305][310]. - The company continues to monitor credit risk associated with its financial instruments, maintaining a strong position with no significant write-offs in accounts receivable[306]. Employee Compensation - HealthEquity's Total Rewards package aims to promote pay equity and includes base salary, incentive pay, and health benefits[78].

Financial Performance and Profitability - The company has incurred significant losses each year since inception and cannot assure future profitability[70] - The company has an accumulated deficit of $726.4 million as of December 31, 2025, and has incurred significant losses each year since inception[106] - The ability to generate sufficient cash flow to meet debt obligations is dependent on financial performance and economic conditions[207] - Insufficient cash flows may force the company to delay capital expenditures or restructure debt, potentially harming business operations[208] - The company may face challenges in refinancing debt or obtaining additional financing due to existing liens and restrictive covenants[209] Revenue Concentration and Customer Relationships - In fiscal years 2025 and 2024, four and three customers respectively accounted for over 10% of total revenue, contributing to 89% and 88% of total revenue[82] - The company relies heavily on a small number of customers, and the loss of any major customer could materially impact financial results[82] - Achieving renewal or expansion of customer relationships may require costly sales efforts that may not yield additional sales[86] - The company’s ability to provide high-quality technical support is crucial for maintaining customer relationships and could impact its financial condition if not met[141] Market and Competitive Environment - Revenue growth rate has declined in the past and may continue to do so due to factors such as increased competition and customer contract terminations[73] - The company faces intense competition from larger competitors with greater resources, which may lead to price reductions and loss of market share[98] - The market for the company's products and services is still emerging and may not achieve expected growth potential, leading to potential inaccuracies in market size estimates[97] Operational Risks and Challenges - The company's results of operations are subject to significant fluctuations, making it difficult to predict future performance[74] - The timing of sales and revenue recognition is unpredictable, leading to potential adverse effects on quarterly or annual operating results[78] - The business is capital intensive, and the company may struggle to finance its capital needs adequately[75] - The company may not be able to convert its backlog into revenue, as contracts may not result in actual revenue and timing of revenue recognition could change[91] Regulatory and Compliance Issues - The business is subject to extensive and evolving government regulations, and failure to comply could adversely affect operations[75] - The company faces risks related to government contracts, including potential changes in policies, funding levels, and compliance requirements that could negatively impact its business[146] - The company is subject to the Defense Federal Acquisition Regulation Supplement (DFARS) and Department of Defense (DoD) cybersecurity requirements, which may increase costs or delay contract awards[160] - Regulatory compliance is critical, as failure to meet requirements could result in penalties or operational delays[218] Cybersecurity and Data Protection - Cybersecurity threats pose significant risks to the company's operations, potentially leading to unauthorized access, data loss, and business disruptions[107] - The company has implemented multiple layers of security measures to protect data and systems, but remains vulnerable to evolving cyber threats[109] - The company maintains cyber liability insurance, but there is uncertainty regarding the adequacy of coverage for potential liabilities[116] - Increasing regulatory focus on privacy and data protection laws may expose the company to higher compliance costs and potential liabilities[243] Technology and Innovation - The company expects to derive a substantial portion of its revenue from products and services based on leading technologies, including artificial intelligence and machine learning[118] - Significant financial resources will be needed to develop new offerings and technologies, with ongoing investments in AI and ML anticipated[119] - There is uncertainty regarding the ability to develop and market innovative technologies that meet customer needs, which could impact growth and business strategy[122] - AI technologies integrated into the company's offerings present risks, including potential flaws in algorithms and datasets, which could harm reputation and customer satisfaction[128] Supply Chain and Manufacturing Risks - The company relies on a limited number of vendors for key raw materials and services, and any failure by these vendors could materially affect business operations and financial condition[185] - Supply chain disruptions, including shortages of materials and equipment, could negatively impact the company's ability to manufacture satellites efficiently, affecting financial results[184] - Manufacturing, testing, and launching satellites involve complex processes, and any failures could materially affect the company's business and financial condition[180] Strategic Alliances and Joint Ventures - The company expects to continue entering into joint ventures and strategic alliances, which may involve significant investments and present risks that could adversely affect business operations[250] - Regulatory scrutiny may limit the company's ability to enter into desired strategic alliances, impacting long-term business strategy[251] Financial and Stockholder Considerations - The company currently benefits from smaller reporting company status, which may limit the comparability of its financial performance with other public companies[257] - There are no current plans to pay cash dividends on Class A common stock, meaning returns on investment depend solely on stock price appreciation[258] - The trading price of Class A common stock may be volatile due to various factors, including market conditions and changes in investor expectations[254] - Anti-takeover provisions in the company's organizational documents could delay or prevent beneficial changes of control[262]

Revenue Performance - Full-year 2025 revenue reached $838.7 million, a 14.6% increase from $731.6 million in 2024[2] - Fourth-quarter 2025 revenue was $170.3 million, up 19.6% year-over-year from $142.4 million in Q4 2024[3] - Revenue for 2025 was $838.7 million, an increase of 14.6% from $731.6 million in 2024[23] - Revenue for the year ended December 31, 2025, increased to $838.7 million, up from $731.6 million in 2024, representing a growth of 14.6%[39] Income and Loss - Adjusted net income for 2025 was $217.0 million, compared to $136.4 million in 2024, reflecting a significant increase[2] - For the year ended December 31, 2025, the company reported a net loss of $130.2 million compared to a net income of $134.8 million in 2024, representing a significant decline[23] - The net loss for the year ended December 31, 2025, was $130.2 million, compared to a net income of $134.8 million in 2024, marking a shift of $265.0 million[39] - The fourth quarter of 2025 saw a net loss of $195.9 million, compared to a net loss of $9.7 million in the same period of 2024, reflecting a substantial increase in losses[23] - Net loss per share of Class A common stock for the year ended December 31, 2025, was $(0.18) based on 12.7 million shares outstanding[42] Guidance and Projections - 2026 revenue guidance is projected to be between $955 million and $970 million, indicating a growth rate of approximately 14% to 15%[3] - The company anticipates a net loss for 2026 due to strategic investments in talent, technology, and acquisitions[3] Client Engagement and Growth - Total client groups served increased to 12,350 in 2025, a 5.6% rise from 11,700 in 2024[12] - The number of client engagements rose to over 22,450, representing a 10.6% increase from 20,300 in 2024[12] Operating Expenses and Costs - Operating expenses for 2025 totaled $974.0 million, a significant increase from $602.0 million in 2024, primarily due to equity restructuring costs of $193.2 million[39] - The company incurred equity restructuring costs of $193.2 million in 2025 as part of its reorganization transactions[23] - Transaction costs for 2025 amounted to $7.4 million, significantly higher than $1.6 million in 2024, indicating increased expenses related to restructuring and planned mergers[23] Cash and Liquidity - As of December 31, 2025, cash and cash equivalents totaled $258.5 million, providing a solid liquidity position[28] - Cash and cash equivalents at the end of 2025 were $250.3 million, a substantial increase from $88.0 million at the end of 2024[45] - Total current assets rose to $412.0 million in 2025, compared to $246.4 million in 2024, reflecting a growth of 67.2%[45] Equity and Distributions - The company recognized $136.5 million in equity-based compensation expense associated with pre-IPO profits interest unit grants during 2025[23] - The company declared and/or paid distributions totaling $264.9 million related to members' tax obligations during the year ended December 31, 2025[29] EBITDA and Margins - Adjusted EBITDA for 2025 is projected to be between $213 million and $220 million, with margins of approximately 22% to 23%[3] - Adjusted EBITDA for 2025 was $226.3 million, up from $142.7 million in 2024, resulting in an adjusted EBITDA margin of 27.0%[23] - The net loss margin for 2025 was (15.5)%, a stark contrast to the net income margin of 18.4% in 2024[23] Market Strategy - The company plans to continue its market expansion and product development initiatives, although specific details were not disclosed in the earnings call[42]

Financial Performance - The company reported a net loss of $35.2 million for the year ended December 31, 2025, compared to a net loss of $51.3 million for 2024, with an accumulated deficit of $241.0 million as of December 31, 2025[127]. - The company has incurred losses since its inception in 2017 and expects to continue incurring significant expenses and operating losses over the next several years[125]. - The company requires substantial additional funding to meet its financial needs and pursue business objectives, with a recent financing of $40.0 million completed in March 2026[138]. - The company has no products approved for commercial sale and has not generated any revenue from product sales, relying on equity offerings and debt financings for funding[125][140]. - The trading price of the company's common stock has been volatile, which may impact its ability to raise capital and expand operations[128][132]. - The company anticipates significant additional capital may be needed in the future to continue planned operations, which could involve selling common stock or other equity securities[300]. - As of December 31, 2025, there are 8,741,473 pre-funded warrants currently exercisable, with 2,952,000 outstanding, which will result in dilution to stockholders upon exercise[301]. - The company does not anticipate paying any cash dividends on its common stock in the foreseeable future, relying instead on capital appreciation for returns[309]. Drug Development and Clinical Trials - The company announced that the Phase 2 part of the EBO-301 study met its primary objective with a clinical response rate of 39.5% for epetraborole + OBR compared to 25.0% for placebo + OBR, but the key secondary endpoint of sputum culture conversion was similar between treatment arms[126]. - The company plans to continue its ongoing and planned preclinical, nonclinical, and clinical development of product candidates, as well as seek regulatory approvals for those that successfully complete clinical trials[129][137]. - The success of product candidates depends on timely regulatory approvals and the ability to manufacture sufficient quantities for clinical trials and commercialization[149]. - There is a high failure rate for product candidates in clinical trials, with significant setbacks occurring even after promising early results[152]. - The company may face delays or additional requirements from regulatory authorities, impacting the timeline for obtaining approvals[155]. - The company has experienced enrollment delays in the past, which could increase development costs and necessitate raising additional capital earlier than planned[170]. - The company may seek accelerated approval for certain product candidates, but if unable to do so, additional clinical trials may be required, increasing costs and delaying regulatory approvals[266]. - The FDA may grant accelerated approval for a product candidate if it provides meaningful therapeutic benefits over existing therapies, but this approval is contingent on the completion of additional confirmatory studies[267]. Regulatory and Compliance Risks - The company faces significant risks related to drug development, including the uncertainty of achieving regulatory approval and commercial success for its product candidates[131]. - Compliance with regulatory requirements is essential, and failure to do so could result in refusal of approval based on clinical data and potential legal consequences[178]. - The company must comply with pricing reporting obligations under U.S. governmental pricing programs, which could lead to civil monetary penalties for errors or failures in reporting[278]. - Relationships with healthcare professionals and third-party payors are subject to anti-kickback and fraud laws, exposing the company to potential penalties[279]. - The company faces risks related to employee misconduct or non-compliance with regulatory standards, which could result in significant penalties and reputational harm[277]. - The FDA's policies and regulations may change, potentially delaying marketing authorization for product candidates[274]. - Failure to obtain regulatory approval or to comply with ongoing requirements could lead to product recalls or withdrawal from the market[273]. Intellectual Property and Licensing - The company relies on licenses from third parties, including Anacor, for critical intellectual property necessary for the development of product candidates[225]. - The patent application process is expensive and time-consuming, and there is uncertainty regarding the issuance and enforceability of patents[224]. - The company may face challenges in maintaining its patent rights, which could allow competitors to commercialize similar technologies[223]. - The company faces risks related to the potential termination of license agreements, which could hinder its ability to develop and commercialize products[228]. - Disputes over intellectual property rights could adversely affect the company's business and financial condition[229]. - The biotechnology and pharmaceutical industries are prone to substantial intellectual property litigation, which could significantly harm the company's business[236]. - The company may not have sufficient financial resources to pursue infringement claims, which could last for years and may not yield commercially valuable outcomes[234]. Operational Challenges - The company has identified material weaknesses in its internal control over financial reporting, which may affect its ability to accurately report financial conditions[124]. - The company lacks a sales and marketing infrastructure, which may delay the commercialization of approved products[198]. - The company may face challenges in recruiting and retaining effective sales and marketing personnel, impacting its ability to promote products[200]. - The company lacks sufficient personnel and resources, which may lead to higher workloads and employee dissatisfaction, impacting retention of key personnel[210]. - The company may encounter difficulties in managing growth if it engages in future acquisitions or strategic collaborations, which could increase capital requirements and dilute stockholder value[216]. Market and Competitive Landscape - The company faces substantial competition from major pharmaceutical and biotechnology companies, which may impact its market position and product development timelines[194]. - The market acceptance of product candidates is uncertain and depends on factors such as safety, efficacy, and reimbursement availability[192]. - The company may face challenges related to international marketing of its product candidates, including differing regulatory requirements and economic instability in foreign markets[206]. - Legislative changes, such as the Inflation Reduction Act of 2022, may impact the company's ability to commercialize product candidates and could lead to reduced demand for its products[282]. - The One Big Beautiful Bill Act enacted in July 2025 is expected to significantly reduce Medicaid funding, potentially decreasing enrollment and services covered, adversely affecting product sales[285]. Cybersecurity and IT Risks - Significant disruptions to information technology systems or cybersecurity incidents could result in financial, legal, regulatory, business, and reputational harm to the company[319]. - The company is increasingly dependent on information technology systems, which are vulnerable to various cybersecurity threats, including sophisticated attacks utilizing AI[319]. - Cybersecurity incidents are increasing in frequency and sophistication, posing risks to the confidentiality, integrity, and availability of the company's information technology systems[320]. - Any unauthorized access or disclosure of information could disrupt business operations and result in significant legal and financial exposure[321]. Emerging Growth Company Status - The company is classified as an "emerging growth company," which allows it to rely on exemptions from certain disclosure requirements, potentially making its stock less attractive to investors[322]. - Reduced reporting burdens in Annual Reports on Form 10-K include only two comparative periods of audited financial statements[322]. - The company cannot predict the impact of its emerging growth company status on investor attractiveness or stock price volatility[322].

Passenger Traffic and Operations - In 2025, domestic passengers increased to 44.5 million, an 8.6% rise from 2024, while international passengers reached 34.1 million, an 11.0% increase [736]. - Total passenger traffic for 2025 was 86.7 million, reflecting a 9.8% growth compared to 2024, while cargo volumes rose to 403.7 thousand tons, a 1.4% increase [736]. - Total aircraft movements in 2025 reached 876.4 thousand, a 6.4% increase from 2024, while the previous year saw a decrease of 3.0% [736]. - Total passengers for 2025 reached 47.4 million, a 12.6% increase from 42.1 million in 2024 [737]. - Aircraft movements totaled 449.7 thousand, a 7.1% increase from 421.0 thousand in 2024 [737]. Financial Performance - Total consolidated revenue for 2025 reached $1,962.1 million, a 6.4% increase from $1,843.3 million in 2024 [740]. - Aeronautical revenue accounted for $934.7 million, maintaining 47.6% of total revenue, consistent with 2024 [740]. - Commercial revenue increased to $813.1 million, representing 41.4% of total revenue, up from 40.1% in 2024 [740]. - Total expenses for 2025 were $1,835.6 million, a 11.1% increase from $1,652.2 million in 2024 [742]. - Financial loss for 2025 was $244.0 million, a significant increase from a gain of $110.3 million in 2024 [742]. - Adjusted EBITDA for 2025 was $727.8 million, a 15.8% increase from $628.7 million in 2024 [747]. - Operating income for 2025 was $488.3 million, reflecting a 9.2% increase from $447.3 million in 2024 [749]. - Income from continuing operations for 2025 was $257.7 million, a decrease of 16.3% compared to $307.9 million in 2024 [749]. Revenue Breakdown - The company’s revenue from Argentina accounted for 54.5% of total revenue in 2025, totaling $1,069.5 million [751]. - Revenue from continuing operations for the year ended December 31, 2025, was U.S.$1,962.1 million, a 6.4% increase from U.S.$1,843.3 million in 2024 [757]. - Revenue from Argentina was U.S.$1,069.5 million for 2025, a 2.5% increase from U.S.$1,043.9 million in 2024 [758]. - Revenue from Italy increased by 22.8% to U.S.$170.4 million in 2025, up from U.S.$138.8 million in 2024 [758]. - Revenue from Brazil was U.S.$118.5 million for 2025, a 6.7% increase from U.S.$111.1 million in 2024 [759]. - Revenue from Uruguay was U.S.$192.2 million for 2025, a 3.5% increase from U.S.$185.7 million in 2024 [760]. - Revenue from Armenia was U.S.$296.3 million for 2025, a 17.2% increase from U.S.$252.8 million in 2024 [763]. - Revenue from Ecuador was U.S.$114.4 million for 2025, a 3.8% increase from U.S.$110.3 million in 2024 [762]. Cost and Expenses - Cost of services comprised $1,272.4 million, making up 69.3% of total expenses, compared to 74.9% in 2024 [742]. - Construction service revenue decreased to $205.8 million, accounting for 10.5% of total revenue, down from 12.1% in 2024 [740]. - Total cost of services increased by 2.8% to $1,272.4 million in 2025, compared to $1,237.3 million in 2024 [749]. - Selling, general and administrative expenses rose by 11.2% to U.S.$220.2 million for the year ended December 31, 2025, compared to U.S.$198.1 million in 2024 [778]. Capital Expenditures and Investments - The company submitted a capital investment program of $425 million to the Armenian Government for infrastructure development at Zvartnots International Airport, to be executed by 2033 [729]. - Capital expenditures in Argentina for 2025 totaled U.S.$123.7 million, primarily for airport renovations and expansions [809]. - An investment plan for Florence Airport is set to invest approximately €480 million from 2025 to 2030, pending final approval [815]. - In 2025, the company spent U.S.$21.1 million at Zvartnots Airport for runway renovation and terminal expansion, and U.S.$0.9 million at Shirak Airport [831]. Economic and Regulatory Environment - The company operates in a hyperinflationary economy in Argentina, with inflation rates reported at 211.4% in 2023, 117.8% in 2024, and 31.5% in 2025 [734]. - The company has identified potential risks from the ongoing conflict between Russia and Ukraine, which may disrupt operations, particularly in Armenia [843]. - The company is subject to various statutory restrictions on dividend distributions, which may affect cash availability at the holding company level [847]. - Payment of dividends to non-resident shareholders from distributable profits is allowed starting from January 1, 2025, under specific conditions [863]. Cash Flow and Financing - The net cash provided by operating activities increased by 14.8% to U.S.$465.2 million for the year ended December 31, 2025, compared to U.S.$405.3 million in 2024 [906]. - The net cash used in investing activities rose by 121.3% to U.S.$71.9 million for the year ended December 31, 2025, from U.S.$32.5 million in 2024 [907]. - The company does not currently enter into any hedging arrangements to manage cash needs [910]. - The company is subject to certain negative covenants under its financing agreements, including restrictions on incurring additional debt and paying dividends [914].

Clinical Trial Results - Seralutinib demonstrated a placebo-adjusted improvement in the primary endpoint, six-minute walk distance (6MWD) at Week 24, of 13.3 meters (p = 0.0320) in the Phase 3 PROSERA Trial involving 390 PAH patients [26]. - In the high-risk subgroup (n = 234), seralutinib showed a 20.0 meters placebo-adjusted improvement in 6MWD (nominal p = 0.0207) and three of four key secondary endpoints had nominal p-values below 0.0125 [26]. - The Phase 2 TORREY trial showed a statistically significant, placebo-adjusted improvement of 14.3% in pulmonary vascular resistance (PVR) and a 732 ng/L decrease in NT-proBNP levels (nominal p = 0.0002) [28][30]. - In the completed Phase 2 TORREY Study, seralutinib demonstrated a placebo-adjusted improvement in pulmonary vascular resistance (PVR) of 14.3% (96.1 dynes × seconds/cm, p = 0.0310) over 24 weeks [59]. - The key secondary endpoint in the TORREY Study showed a mean difference in 6-minute walk distance (6MWD) of 6.5 meters favoring the seralutinib arm, although not statistically significant [59]. - Seralutinib treatment resulted in a placebo-adjusted reduction in NT-proBNP of 408.3 ng/L at Week 24 (p = 0.0012), indicating a significant improvement in right heart stress [60]. - In the PROSERA Phase 3 study, seralutinib showed a placebo-adjusted improvement in 6MWD of 13.3 meters at Week 24 (p = 0.0320), with a median change from baseline of 28.2 meters for seralutinib versus 13.5 meters for placebo [64]. - In patients with REVEAL Lite 2 score ≥6, seralutinib showed a placebo-adjusted NT-proBNP location shift of -265.8 ng/L at Week 24 (nominal p = 0.0002) and an odds ratio of 2.033 for ≥1-point improvement in REVEAL Lite 2 risk score [66]. - In patients with CTD-APAH, seralutinib achieved a placebo-adjusted gain of 37.0 meters in six-minute walk distance at Week 24 (nominal p = 0.0104) [67]. - The TORREY study reported treatment emergent adverse events (TEAEs) in 86% of placebo and 93% of seralutinib patients, with the majority being mild to moderate in severity [61]. - Seralutinib was well-tolerated in the Phase 1b trial, with no serious adverse events reported and common adverse events being mild-to-moderate cough and headache [56]. - The Phase 1a studies indicated that seralutinib was rapidly absorbed and cleared from the systemic circulation, with no dose-limiting toxicities observed [55]. - Treatment-emergent adverse events (TEAEs) were reported in 86.5% of patients receiving seralutinib, with the most common adverse event being cough at 37.0% [69]. Regulatory and Development Plans - The company plans to engage with the FDA to define a regulatory path forward for seralutinib and anticipates a potential approval action date by year-end 2027 [24]. - The company is advancing preparations for a potential NDA submission based on ongoing analyses of the PROSERA dataset and FDA feedback [24]. - The FDA's approval process for seralutinib will follow the Investigational New Drug (IND) framework and seek approval through the New Drug Application (NDA) pathway [96]. - The FDA aims to complete the review of a standard NDA for a new molecular entity within ten months from the filing date, although the typical review duration is twelve months [110]. - The FDA may issue a Complete Response Letter if the NDA has deficiencies, requiring the sponsor to address these issues before resubmission [112]. - Orphan Drug Designation is granted for drugs intended to treat rare diseases affecting fewer than 200,000 individuals in the U.S., providing exclusivity for seven years upon first approval [115][118]. - Fast track designation allows for expedited review of drugs intended for serious conditions, enabling rolling submissions of NDA sections [120][124]. - Priority review designation aims for a six-month review period for drugs that significantly improve safety or effectiveness over existing treatments [122]. - Accelerated approval may be granted based on surrogate endpoints that predict clinical benefit, with confirmatory trials required post-approval [123]. - The FDA imposes post-approval requirements, including potential Phase 4 clinical trials to monitor safety and effectiveness after commercialization [125]. - Non-patent data exclusivity under the FDCA provides a five-year period for the first NDA approval of a new chemical entity, preventing other applications based on the same active moiety during this time [128]. - The FDCA provides three years of non-patent exclusivity for an NDA if new clinical investigations are deemed essential for approval [129]. - Pediatric exclusivity can grant an additional six months of marketing exclusivity if clinical trials in children are conducted in response to an FDA request [130]. Financial and Market Considerations - The estimated PAH patient population in the US is about 50,000 patients, and in the EU, it exceeds 70,000 patients, indicating a growing market for PAH therapies [48]. - Newly diagnosed functional class III and IV PAH patients have 5-year survival rates of 60% and 44%, respectively, highlighting the high morbidity and mortality associated with the disease [47]. - The company has incurred net losses of $170.4 million and $56.5 million for the years ended December 31, 2025 and 2024, respectively, with an accumulated deficit of $1,438.9 million as of December 31, 2025 [206]. - The company expects to continue incurring losses for the foreseeable future as it develops and seeks regulatory approval for seralutinib [206]. - The company believes its existing cash, cash equivalents, and marketable securities will fund operations into the first quarter of 2027, but additional capital will be needed for further development [209]. - The company may require substantial additional financing to achieve its goals, and failure to obtain necessary capital could delay or terminate the seralutinib development program [208]. - The company faces significant competition from other biotechnology and pharmaceutical companies, which could adversely affect its operating results [206]. - Sales in the U.S. depend on sufficient coverage and adequate reimbursement from third-party payors, including government health programs [131]. - Coverage and reimbursement decisions by third-party payors can differ significantly, impacting the successful commercialization of products [132]. - The Inflation Reduction Act (IRA) enacted in 2022 requires price negotiations for certain drugs with Medicare, potentially affecting revenue [140]. - The One Big Beautiful Bill Act, enacted in July 2025, is expected to reduce Medicaid funding, impacting revenue generation [141]. - The Trump administration's proposed regulations could impose significant changes to drug pricing, affecting the pharmaceutical market [142]. - Legislative measures at the state level are increasingly controlling pharmaceutical pricing, which could harm business prospects [143]. Collaboration and Partnerships - A collaboration agreement with Chiesi was established for the joint development of seralutinib, with both parties contributing 50% of commercial efforts in the U.S. [32]. - The collaboration agreement with Chiesi focuses on the development and commercialization of seralutinib for PAH and PH-ILD, with both parties sharing development costs equally [86]. - Chiesi agreed to pay the company $160.0 million as reimbursement for development costs, with potential additional payments of up to $146.0 million in regulatory milestones and $180.0 million in sales milestones [88]. - The collaboration agreement allows for equal sharing of commercial profits and losses in the United States, while in the ROW Territory, Chiesi will pay an escalating mid-to-high teens percentage royalty on net sales of the Licensed Product [88]. Intellectual Property and Compliance - The company has exclusively licensed two issued U.S. patents for seralutinib, which are not due to expire before 2037, and several patents in other jurisdictions with similar expiration timelines [93]. - The company aims to protect its proprietary technology through patents, trade secrets, and market exclusivity, which are crucial for its commercial success [92]. - The company must comply with its license agreements to maintain rights to seralutinib, and failure to do so could result in loss of those rights [206]. - The company is subject to extensive government regulations regarding the research, development, testing, and marketing of its products, which require significant time and financial resources [94]. - The company must comply with numerous U.S. data privacy and security laws, which can result in significant civil and criminal penalties for non-compliance [156]. - To market products outside the U.S., the company needs to adhere to varying regulatory requirements regarding quality, safety, and efficacy [157]. - Regulatory approval processes in foreign jurisdictions may differ significantly from the U.S., potentially leading to longer approval times [158]. - The EU Clinical Trials Regulation (CTR) became applicable on January 31, 2022, streamlining the clinical trial application process across member states [164]. - The maximum timeframe for the evaluation of a Marketing Authorization Application (MAA) by the EMA is 210 days, with potential accelerated reviews in exceptional cases [169]. - New products authorized for marketing in the EU generally receive eight years of data exclusivity and an additional two years of market exclusivity upon MAA [172]. - Orphan medicinal products in the EU are entitled to a ten-year period of market exclusivity, which can be extended by two years if they comply with an agreed pediatric investigation plan [176]. - The holder of a Marketing Authorization must establish a pharmacovigilance system and report suspected serious adverse reactions [178]. - All new MAAs must include a risk management plan detailing measures to minimize risks associated with the product [179]. Company Operations and Workforce - The company has a limited operating history and has incurred significant operating losses since its inception, expecting to continue incurring losses for the foreseeable future [203]. - The company requires substantial additional financing to achieve its goals, particularly in advancing seralutinib through clinical development [203]. - As of March 10, 2026, the company had 161 full-time employees, with 20% holding a Ph.D. or M.D., and 59% of the workforce being women [199]. - The company has assembled a highly skilled team of industry veterans, scientists, and clinicians to support its operations and goals [197]. - The company considers its relationship with employees to be good, with no employees represented by labor unions or covered by collective bargaining agreements [199]. - The company has sold $200.0 million in aggregate principal amount of 5.00% convertible senior notes due 2027 and has approximately $96.5 million of other liabilities [212]. - The company’s stock price is volatile, and investors may incur substantial losses as a result [206]. - The company may seek additional capital due to favorable market conditions or strategic considerations, even if it believes it has sufficient funds for current operations [211].